GLP-1s are known to improved knee OA. Using a mouse OA model w/ obesity, semaglutide yielded less pain, osteophytes & had strong chondroprotective effects, fia a wt loss-independent way. Changing from glycolysis to oxidative phosphorylation resulted in cartilage restoration. https://t.co/8zs34ys9o9

What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these https://t.co/nuXGUdmwon

Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://t.co/cXTQ2TWyHZ

A month ago the FDA Granted Breakthrough Designation to Ianalumab for Sjögren Disease . The drug targets BAFF and depletes B cells. Two recent positive RCTs (NEPTUNUS-1, NEPTUNUS-2). Novartis expects a regulatory decision in early 2026 https://t.co/PXVjGG1Cmd https://t.co/0s5livw1bg

FDA has approved tocilizumab-anoh (Avtozma; Celltrion), a biosimilar to Actemra, for intravenous and subcutaneous use in rheumatoid arthritis (RA), giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. https://t.co/qw7SJ7ZCK9

Taiwan National retrospective study (2001-20) of 8732 newly Dx, biologic-naïve RA pts initiating b/tsDMARDs. Found no difference in malignancy event rates between DMARDs. 2.16% over 5-yr & 2.89% over 18yrs. (6384 Rx w/ TNFis, 667 w/ TCZ, 656 w/ ABA, 1025 on tsDMARDs) https://t.co/54ZMPywEYI

Should I become a physician or physician assistant/associate? Practical overview from US News. KEY QUESTIONS: 1) which is harder to get into? 2) Career flexibility? 3) Work-Life balance? 4) Which fits for you? Both are a lifelong commitment to patient care. https://t.co/szv1nUmkYQ

Is Giant cell arteritis over diagnosed or over-referred? Caution IF the patient is: 1) under age 50yrs; 2) has Hx of chronic HA or migraine; 3) has normal ESR/CRP. Why not consider screen w/ Giant Cell Arteritis Probability Score (needing 9.5/32 points) https://t.co/qnCWgzjYJ4 https://t.co/LT6atm0m8f

UK Retrospective analysis of 2 RA cohorts, 2,701 pts (F/U 6 yrs) = 101 (3.7%) Dx with ILD. (12 @ baseline, 46 w/ F/U, 43 @ death). ILD Dx signif. assoc w/ onset age (aOR 1.03), seropositivity (aOR 2.58), ever smoking (aOR 1.7). https://t.co/Zvkb1Wjpa4 https://t.co/YMkWDc3rMr

Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb https://t.co/UTPqa9erPU

AMA survey of 502 nurse practitioners (95% work on a MD-led team - 88% were satisfied; Half very satisfied working w/ MDs. 94% valued physician mentorship;  89% cited patient safety as a key benefit to physician-led care; and  88% listed liability protection as a key benefit. https://t.co/SVvr3XEQSz

American College of Chest Physicians has announced that advanced practice providers (APPs) can earn the CHEST Critical Care Advanced Practice Provider (CCAPP) designation; CCAPP Certification exam designed to validate clinical competence & Enhanced credibility/recognition https://t.co/Ip6YMjwOBc